Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alogliptin monotherapy in adults with relapsed type 2 diabetes after remission
ChiCTR2500103072Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alogliptin in type 2 diabetes mellitus (T2DM), sponsored by Tongji Hospital. Primary endpoint: Glycated hemoglobin. Planned start May 2025; status: not yet recruiting.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500103072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103072.